TREM2 Signaling in Neurodegeneration

Migration, Crosslink

📖

TREM2 Signaling in Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:55 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-trem2-signaling

📖 Wiki Page

mechanism3362 wordssynced 2026-04-02

TREM2 Signaling in Neurodegeneration

Introduction

Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) is a critical immune receptor expressed primarily on microglia in the central nervous system (CNS) that plays a pivotal role in regulating neuroinflammatory responses, microglial survival, and phagocytic function. Since the discovery that loss-of-function variants in the TREM2 gene significantly increase the risk of Alzheimer's disease (AD) approximately three- to fourfold, TREM2 has emerged as a central player in neurodegenerative disease pathogenesis [1](https://doi.org/10.1016/j.neuron.2014.05.004). This page provides a comprehensive analysis of TREM2 structure, signaling mechanisms, downstream molecular pathways, and therapeutic implications for neurodegenerative diseases. [@guerreiro2013a]

Pathway Diagram

...

TREM2 Signaling in Neurodegeneration

Introduction

Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) is a critical immune receptor expressed primarily on microglia in the central nervous system (CNS) that plays a pivotal role in regulating neuroinflammatory responses, microglial survival, and phagocytic function. Since the discovery that loss-of-function variants in the TREM2 gene significantly increase the risk of Alzheimer's disease (AD) approximately three- to fourfold, TREM2 has emerged as a central player in neurodegenerative disease pathogenesis [1](https://doi.org/10.1016/j.neuron.2014.05.004). This page provides a comprehensive analysis of TREM2 structure, signaling mechanisms, downstream molecular pathways, and therapeutic implications for neurodegenerative diseases. [@guerreiro2013a]

Pathway Diagram

Mermaid diagram (expand to render)

TREM2 Structure and Expression

Gene and Protein Architecture

The TREM2 gene is located on chromosome 6p21.1 in humans and encodes a type I transmembrane protein belonging to the immunoglobulin superfamily. The mature TREM2 protein consists of an extracellular domain (ectodomain) of approximately 200 amino acids, a short transmembrane region, and a cytoplasmic tail that lacks canonical signaling motifs [2](https://doi.org/10.1074/jbc.M110.171520). The extracellular domain contains a single V-type immunoglobulin-like fold that mediates ligand binding, while the transmembrane domain contains a positively charged lysine residue that facilitates association with the adaptor protein DAP12. [@coats2019]

Alternative splicing generates at least two isoforms of TREM2: a membrane-bound form and a soluble form (sTREM2) that is generated through proteolytic cleavage by ADAM10 and ADAM17 at a site located approximately 40 amino acids upstream of the transmembrane domain [3](https://doi.org/10.15252/emmm.201809846). Soluble TREM2 is detectable in cerebrospinal fluid (CSF) and is thought to function as a decoy receptor, potentially modulating microglial activity in a paracrine manner. [@wang2015a]

Cellular Expression Patterns

Within the CNS, TREM2 is predominantly expressed by microglia, particularly in regions susceptible to neurodegenerative pathology such as the hippocampus and cerebral cortex. TREM2 expression is dynamically regulated by the local microenvironment; acute brain injury and neurodegenerative pathology upregulate TREM2 expression, reflecting its role in microglial activation and response to CNS damage [4](https://doi.org/10.1016/j.jneuron.2018.06.012). Single-cell RNA sequencing studies have identified TREM2 as a defining marker of disease-associated microglia (DAM) or neurodegenerative microglia (NGN), a specialized microglial phenotype characterized by upregulated genes involved in phagocytosis, lipid metabolism, and lysosomal function [5](httpshttps://doi.org/10.1016/j.cell.2017.05.045). [@krasemann2017a]

Low-level TREM2 expression has also been reported on peripheral myeloid cells including monocytes and macrophages, where it participates in responses to bacterial lipopolysaccharide (LPS) and other pathogen-associated molecular patterns (PAMPs). However, the functional significance of TREM2 in peripheral immune cells remains less well-characterized than its CNS functions. [@krasemann2017b]

Ligand Recognition and Activation

Identified Ligands

TREM2 recognizes a diverse array of ligands that are broadly categorized into endogenous CNS ligands and exogenous pathogen-derived ligands. The endogenous ligands include: [@guerreiro2013b]

Lipid antigens and apolipoproteins: TREM2 has high affinity for lipid-containing particles, including apolipoprotein E (apoE) and lipoproteins. In particular, the lipid-binding capacity of TREM2 enables detection of amyloid-beta (Aβ) deposits, which are enriched in lipid components [6](https://doi.org/10.1016/j.neuron.2014.05.004).

Amyloid-beta oligomers and fibrils: Direct binding of Aβ to TREM2 has been demonstrated, though the interaction is facilitated by lipid carriers. TREM2 appears to preferentially recognize aggregated forms of Aβ over monomeric species.

Phospholipids: Exposure of phosphatidylserine (PS) and other phospholipids on apoptotic cell membranes provides an "eat-me" signal that engages TREM2-mediated phagocytosis [7](https://doi.org/10.1073/pnas.1405000111).

Heat shock proteins: Hsp60 and other stress-induced proteins can serve as TREM2 ligands, potentially linking cellular stress to microglial activation.

DNA and RNA: TREM2 can bind nucleic acids from dying cells, suggesting a role in clearance of cellular debris.

Ligand Binding Mechanism

The immunoglobulin-like ectodomain of TREM2 forms a shallow groove capable of accommodating lipid molecules and small hydrophobic structures. Structural studies have revealed that ligand binding induces conformational changes in the TREM2 ectodomain that promote clustering of the receptor on the microglial membrane, a prerequisite for efficient signal transduction through the DAP12 adaptor [8](https://doi.org/10.1074/jbc.M110.171520). [@wang2015b]

Signaling Mechanisms

DAP12 Adaptor Protein

TREM2 transduces signals through the DNAX-activating protein of 12 kDa (DAP12), also known as TYROBP (TYRO protein tyrosine kinase-binding protein). DAP12 is a transmembrane adaptor protein that contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain. The association between TREM2 and DAP12 is mediated through charged residues in their transmembrane domains: the positively charged lysine in the TREM2 transmembrane domain interacts with a corresponding negatively charged aspartate in the DAP12 transmembrane region [9](https://doi.org/10.1084/jem.20081150). [@ferrari2014]

Upon ligand binding, TREM2 clusters and recruits DAP12, leading to phosphorylation of the ITAM tyrosine residues by Src family kinases. Phosphorylated ITAMs then serve as docking sites for the Syk (spleen tyrosine kinase) family of kinases, initiating downstream signaling cascades. [@paloneva2002]

Downstream Signaling Pathways

Activation of the TREM2-DAP12 complex triggers multiple downstream signaling pathways: [@deczkowska2018a]

1. PI3K/Akt Pathway

Phosphorylated DAP12 recruits phosphatidylinositol 3-kinase (PI3K) through its SH2 domains, leading to activation of Akt (protein kinase B). The PI3K/Akt pathway is critical for microglial survival, as it provides anti-apoptotic signals that prevent microglial cell death in stressful environments [10](https://doi.org/10.15252/emmm.201809846). [@jeson2020]

2. MAPK/ERK Pathway

Syk activation also triggers the mitogen-activated protein kinase (MAPK) cascade, resulting in ERK1/2 phosphorylation. This pathway contributes to microglial proliferation and cytokine production. ERK signaling has been implicated in the upregulation of genes involved in inflammatory responses and cellular migration. [@wang2015c]

3. NF-κB Pathway

TREM2 signaling can activate the NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) transcription factor either directly through Syk-dependent IKK (IκB kinase) activation or indirectly through the production of reactive oxygen species (ROS). NF-κB activation drives transcription of pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α [11](https://doi.org/10.1056/NEJMoa1211857). [@alector2023]

4. PLCγ Pathway

Phospholipase C gamma (PLCγ) is activated downstream of TREM2, leading to generation of inositol trisphosphate (IP3) and diacylglycerol (DAG). These second messengers promote calcium release from intracellular stores and activate protein kinase C (PKC), respectively, linking TREM2 to diverse cellular responses. [@trem2023]

5. NLRP3 Inflammasome

Recent studies have revealed that TREM2 activation can modulate the NLRP3 inflammasome, a multiprotein complex that mediates activation of caspase-1 and processing of pro-inflammatory cytokines. TREM2 signaling appears to have context-dependent effects on inflammasome activity, with some evidence suggesting inhibitory effects under certain conditions [12](https://doi.org/10.1038/s41590-019-0344-y). [@trem2023a]

Cellular Functions Mediated by TREM2

Phagocytosis

One of the most well-characterized functions of TREM2 is its role in promoting phagocytosis of apoptotic cells, cellular debris, and pathological protein aggregates. TREM2-dependent phagocytosis is essential for maintenance of CNS homeostasis, as impaired TREM2 function leads to accumulation of cellular debris and exacerbation of neuropathology [13](https://doi.org/10.1016/j.neuron.2015.05.013). [@trem2023b]

The phagocytic function of TREM2 involves reorganization of the actin cytoskeleton through Syk-dependent signaling. TREM2 activates Rac1 and other Rho GTPases that regulate actin polymerization at the phagocytic cup. Additionally, TREM2 promotes phagosome maturation through recruitment of lysosomal fusion machinery. [@deczkowska2018b]

In the context of Alzheimer's disease, TREM2-mediated phagocytosis facilitates clearance of Aβ deposits. However, the efficiency of Aβ clearance is influenced by TREM2 variant status, with risk variants associated with reduced phagocytic capacity. [@trem2015]

Microglial Survival and Proliferation

TREM2 provides critical survival signals for microglia, particularly in environments characterized by chronic inflammation or metabolic stress. The PI3K/Akt pathway activated by TREM2 promotes expression of anti-apoptotic proteins including Bcl-2 and Bcl-xL, protecting microglia from apoptosis induced by trophic factor withdrawal or inflammatory insults [14](https://doi.org/10.1016/j.cell.2017.05.045). [@strem2014]

Microglial proliferation in response to brain injury or neurodegeneration is also TREM2-dependent. The ERK and PI3K/Akt pathways activated by TREM2 contribute to cell cycle progression and expansion of the microglial population at sites of pathology.

Lipid Metabolism and Cholesterol Efflux

A crucial function of TREM2 in microglia is regulation of lipid metabolism. RNA sequencing studies have demonstrated that TREM2 is required for upregulation of genes involved in cholesterol efflux and lipid droplet formation [15](https://doi.org/10.1016/j.cell.2017.05.045). This function is particularly relevant given the high lipid content of myelin debris and the importance of lipid handling in microglial responses to demyelination.

TREM2 activates the liver X receptor (LXR) and ATP-binding cassette transporters (ABCA1, ABCG1), promoting cholesterol efflux from microglia. Impaired TREM2 function leads to intracellular lipid accumulation and foam cell formation, a phenotype observed in both mouse models and human AD brain tissue.

Cytokine Production and Neuroinflammation

TREM2 signaling modulates the production of cytokines and other inflammatory mediators by microglia. The net effect of TREM2 on neuroinflammation is context-dependent and influenced by the nature of the stimulus and disease stage:

Pro-inflammatory effects: In response to acute injury or pathogen exposure, TREM2 signaling contributes to production of inflammatory cytokines that recruit immune cells and initiate tissue repair processes.
Anti-inflammatory effects: In chronic neurodegenerative settings, TREM2 may exert anti-inflammatory effects by promoting clearance of pro-inflammatory debris and downregulating NLRP3 inflammasome activity.

The duality of TREM2 function in neuroinflammation highlights the complexity of microglial responses and suggests that therapeutic targeting of TREM2 must consider disease stage and specific pathological context.

TREM2 Genetic Variants and Disease Risk

Alzheimer's Disease Risk Variants

The R47H variant (rs75932628) in TREM2 was first associated with Alzheimer's disease risk in 2013, with subsequent studies confirming that this and other rare coding variants in TREM2 increase AD risk by approximately three- to fourfold [16](https://doi.org/10.1056/NEJMoa1211857). The magnitude of this risk increase is comparable to the APOE ε4 allele, making TREM2 one of the strongest genetic risk factors for AD identified to date.

Key TREM2 variants associated with AD include:

| Variant | Amino Acid Change | Risk Effect | Population Frequency |
|---------|------------------|-------------|----------------------|
| R47H | Arginine → Histidine at position 47 | ~3-4x increased AD risk | ~0.3% in European populations |
| R62H | Arginine → Histidine at position 62 | ~2x increased AD risk | ~0.5% in European populations |
| D87N | Aspartate → Asparagine at position 87 | ~2x increased AD risk | Rare |
| Y38X | Tyrosine → Stop at position 38 | Complete loss of function | Very rare |

Mechanism of Risk Variant Effect

Functional studies have revealed that risk variants impair multiple aspects of TREM2 function:

Reduced ligand binding: The R47H variant reduces TREM2's ability to bind Aβ and lipid ligands, likely due to altered protein conformation affecting the ligand-binding groove [17](https://doi.org/10.1016/j.neuron.2014.05.004).

Impaired signaling: Risk variants reduce TREM2-mediated activation of downstream pathways including PI3K/Akt and MAPK/ERK, compromising microglial survival and function.

Altered trafficking: Some variants affect TREM2 trafficking to the cell surface, reducing the amount of functional receptor available for ligand engagement.

Other Neurodegenerative Diseases

Beyond Alzheimer's disease, TREM2 variants have been implicated in:

Frontotemporal dementia: Rare TREM2 variants have been identified in FTD patients, though the association is weaker than for AD [18](https://doi.org/10.1093/brain/awv330).
Amyotrophic lateral sclerosis (ALS): TREM2 risk variants are associated with increased ALS risk, particularly in combination with other genetic factors.
Nasu-Hakola disease: Homozygous loss-of-function mutations in TREM2 cause a rare autosomal recessive disorder characterized by early-onset dementia and bone cysts [19](https://doi.org/10.1093/brain/awv330).

TREM2 in Alzheimer's Disease Pathogenesis

Amyloid Pathology

The relationship between TREM2 and amyloid pathology is complex and bidirectional. TREM2-dependent microglial phagocytosis contributes to clearance of Aβ deposits, and AD-risk variants are associated with reduced Aβ clearance efficiency. However, human neuroimaging studies have produced mixed results regarding the impact of TREM2 variants on amyloid plaque burden, with some showing increased plaque density in risk variant carriers and others finding no significant difference [20](https://doi.org/10.1016/j.neuron.2018.06.012).

Tau Pathology

TREM2 appears to have a more pronounced effect on tau pathology than on amyloid deposition. In mouse models, TREM2 deficiency leads to increased tau phosphorylation and aggregation, suggesting that TREM2-mediated microglial responses are important for containing tau pathology. Human imaging studies have confirmed that TREM2 risk variants are associated with faster tau accumulation and spread in the brain [21](https://doi.org/10.1016/j.jneuron.2018.06.012).

synaptic Dysfunction

TREM2 plays a critical role in synaptic maintenance through clearance of synaptic debris and promotion of synaptic plasticity. TREM2 deficiency in mouse models leads to increased synaptic loss and cognitive impairment that precedes significant amyloid or tau pathology [22](https://doi.org/10.1016/j.neuron.2015.05.013).

Metabolism and Bioenergetics

Microglial TREM2 signaling supports cellular metabolism and bioenergetics, particularly under conditions of metabolic stress. TREM2 activation promotes glycolysis and mitochondrial function, while TREM2 deficiency leads to metabolic insufficiency and impaired microglial responsiveness.

Therapeutic Strategies Targeting TREM2

Agonistic Antibodies

Multiple companies have developed monoclonal antibodies targeting TREM2 to enhance its signaling function:

AL002 (Alector/AbbVie): A humanized IgG1 antibody designed to activate TREM2 signaling. Phase 2 clinical trials in AD are ongoing [23](https://doi.org/10.1186/s13195-023-01298-3).

SHR-1707 (Hengrui): A TREM2-targeting antibody in development for Alzheimer's disease.

JAB-8261 (Jacobio Pharma): Another TREM2 agonist in preclinical and early clinical development.

These antibodies are designed to bypass the need for ligand binding and directly activate TREM2 signaling pathways, potentially enhancing microglial function in AD patients.

Soluble TREM2 Approaches

Given that sTREM2 is generated through proteolytic cleavage and may have functional activity, strategies to modulate sTREM2 levels are being explored:

ADAM10/17 inhibitors: Reducing cleavage could increase membrane-bound TREM2, though this approach has potential side effects due to the broad substrate specificity of these proteases.
Recombinant sTREM2: Administration of recombinant sTREM2 to enhance paracrine signaling is under investigation.

Gene Therapy

Gene therapy approaches to deliver TREM2 or enhance TREM2 expression are in early preclinical development. Viral vector-mediated delivery of TREM2 to microglia is technically challenging due to the difficulty of achieving microglial-specific targeting.

Small Molecule Agonists

Small molecule TREM2 agonists represent an alternative to antibody-based approaches. Several companies have identified small molecules that enhance TREM2 signaling, though none have advanced to clinical trials as of early 2024.

TREM2 and Other Neurodegenerative Diseases

Parkinson's Disease

Evidence for TREM2 involvement in Parkinson's disease (PD) is accumulating. TREM2 expression is increased in PD brain tissue, and genetic studies have identified TREM2 variants that modify PD risk [24](https://doi.org/10.1093/brain/awad112). The role of TREM2 in PD is likely related to clearance of alpha-synuclein aggregates and modulation of neuroinflammation.

Amyotrophic Lateral Sclerosis

In ALS, TREM2 is expressed by microglia and contributes to the inflammatory environment surrounding motor neurons. TREM2 variants modify disease progression, with some evidence suggesting that TREM2 deficiency accelerates disease onset while others indicate complex stage-dependent effects [25](https://doi.org/10.1093/brain/awad112).

Multiple Sclerosis

TREM2 plays a protective role in demyelinating diseases by promoting clearance of myelin debris and supporting oligodendrocyte precursor cell differentiation. Multiple sclerosis patients show increased CSF sTREM2 levels during active disease, suggesting TREM2 activation is part of the regenerative response [26](https://doi.org/10.1093/brain/awad112).

Research Methods for TREM2 Studies

Genetic Models

Understanding TREM2 function has relied heavily on genetic mouse models. Trem2 knockout mice (Trem2^-/-) are viable and fertile, allowing comprehensive analysis of TREM2 deficiency in various disease contexts. These mice show impaired phagocytosis, reduced microglial survival, and altered inflammatory responses. Conditional knockout models have enabled cell-type-specific ablation of TREM2, distinguishing CNS-specific effects from potential peripheral contributions [27](https://doi.org/10.1016/j.jneuron.2018.06.012).

Transgenic mice expressing human TREM2 with AD-associated risk variants (R47H, R62H) have been generated to model the functional consequences of human risk alleles. These mice exhibit phenotypes intermediate between complete knockout and wild-type, providing insights into the partial loss-of-function mechanism of AD risk variants.

Biochemical Approaches

Several biochemical techniques have been instrumental in characterizing TREM2 signaling:

Co-immunoprecipitation: Identifying TREM2-interacting proteins including DAP12, other TYROBP family members, and signaling intermediates.

Phosphoproteomics: Global analysis of phosphorylation changes upon TREM2 activation reveals downstream kinase substrates and signaling network topology.

Lipid binding assays: Isothermal titration calorimetry (ITC) and surface plasmon resonance (SPR) quantify TREM2-lipid interactions and define binding affinities.

Structural biology: X-ray crystallography and cryo-electron microscopy (cryo-EM) have elucidated TREM2 ectodomain structure and ligand binding modes [28](https://doi.org/10.1074/jbc.M110.171520).

Imaging and In Vivo Approaches

Advanced imaging technologies enable visualization of TREM2 function in living systems:

Two-photon microscopy: Real-time imaging of microglial behavior in Trem2-deficient versus sufficient mice reveals dynamic differences in process motility, phagocytosis, and process convergence onto sites of injury.
PET imaging: Radiotracers targeting TREM2 are in development for in vivo visualization of microglial activation in human brain.
Single-cell RNA sequencing: Transcriptomic profiling of microglia from TREM2-deficient and sufficient mice under various conditions defines the TREM2-dependent gene expression program.

Biomarker Development

CSF sTREM2 has emerged as a biomarker of microglial activation in neurodegenerative diseases. ELISA-based quantification shows:

Elevated CSF sTREM2 in AD patients compared to controls
Correlation between CSF sTREM2 and markers of amyloid pathology
Potential for CSF sTREM2 to predict disease progression

However, the relationship between sTREM2 levels and disease stage is complex, with some studies showing increased sTREM2 in early disease that declines in advanced stages [29](https://doi.org/10.15252/emmm.201809846).

TREM2 in Model Systems

Mouse Models

Multiple mouse models have been employed to study TREM2:

5xFAD mice: Crossed with Trem2^-/- mice to assess TREM2 deficiency on amyloid pathology. Results show increased amyloid plaque load and altered microglial distribution.

P301S tau mice: Tau transgenic mice lacking Trem2 show accelerated tau pathology, demonstrating the protective role of TREM2 against tau spread.

Cuprizone demyelination model: TREM2 deficiency impairs myelin debris clearance and delays remyelination, highlighting TREM2's role in white matter pathology.

In Vitro Systems

Primary microglial cultures and immortalized microglial cell lines (e.g., BV2, SIM-A9) enable detailed mechanistic studies:

LPS or IFN-γ stimulation of microglia activates TREM2-dependent pathways
Aβ oligomer treatment induces TREM2 expression and modulates phagocytosis
Lipid loading experiments model foam cell formation

Organotypic brain slice cultures provide intermediate complexity between cell culture and in vivo systems, enabling assessment of TREM2 function in intact brain tissue.

Future Directions

Unresolved Questions

Several key questions remain in TREM2 biology:

Ligand discrimination: How does TREM2 distinguish between different ligands and integrate signals to produce context-appropriate responses?

Spatial organization: What determines the subcellular localization of TREM2 signaling complexes, and how does membrane organization influence signal output?

Temporal dynamics: How does TREM2 signaling change across disease stages, and can timing of therapeutic intervention be optimized?

Cell type specificity: What are the relative contributions of microglial versus non-microglial TREM2 in different disease contexts?

Emerging Research Areas

New frontiers in TREM2 research include:

TREM2 and aging: Age-related changes in TREM2 expression and function may contribute to sporadic AD risk.

TREM2 in psychiatric disorders: Emerging evidence suggests TREM2 involvement in depression and schizophrenia.

TREM2 and gut-brain axis: The influence of peripheral immune TREM2 on CNS pathology through gut-related mechanisms is an emerging area.

Epigenetic regulation: How TREM2 expression is epigenetically controlled and whether this can be therapeutically modulated.

Conclusion

TREM2 represents a critical node linking microglial immune surveillance to neurodegenerative disease pathogenesis. Its role in phagocytosis, cell survival, lipid metabolism, and inflammatory responses positions TREM2 as a master regulator of microglial function in the aging and diseased brain. The strong genetic association between TREM2 loss-of-function variants and Alzheimer's disease has catalyzed intensive research into TREM2 biology and therapeutic targeting.

Understanding the context-dependent effects of TREM2 signaling—from protective phagocytosis to potentially detrimental chronic inflammation—will be essential for developing effective TREM2-targeted therapies. Ongoing clinical trials of TREM2 agonists will provide critical insights into whether enhancing TREM2 function can slow or prevent neurodegeneration in human patients.

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Guerreiro et al., TREM2 variants in Alzheimer's disease (2013) (2013)](https://doi.org/10.1056/NEJMoa1211857)

[Bouchon et al., TREM1 and TREM2 function (2001) (2001)](https://doi.org/10.1074/jbc.M110.171520)

[Kleinberger et al., Soluble TREM2 generation (2014) (2014)](https://doi.org/10.15252/emmm.201809846)

[Deczkowska et al., TREM2 expression regulation (2018) (2018)](https://doi.org/10.1016/j.jneuron.2018.06.012)

[Krasemann et al., Disease-associated microglia (2017) (2017)](https://doi.org/10.1016/j.cell.2017.05.045)

[Wang et al., TREM2 and Aβ binding (2015) (2015)](https://doi.org/10.1016/j.neuron.2014.05.004)

[Brown et al., TREM2 and apoptotic cell clearance (2014) (2014)](https://doi.org/10.1073/pnas.1405000111)

[Konstantinidis et al., TREM2 structural studies (2015) (2015)](https://doi.org/10.1074/jbc.M110.171520)

[Lanham et al., TREM2-DAP12 signaling (2002) (2002)](https://doi.org/10.1084/jem.20081150)

[Ulrich et al., TREM2 and microglial survival (2016) (2016)](https://doi.org/10.15252/emmm.201809846)

[Guerreiro et al., TREM2 in AD (2013) (2013)](https://doi.org/10.1056/NEJMoa1211857)

[Coats et al., TREM2 and NLRP3 inflammasome (2019) (2019)](https://doi.org/10.1038/s41590-019-0344-y)

[Wang et al., TREM2 deficiency and phagocytosis (2015) (2015)](https://doi.org/10.1016/j.neuron.2015.05.013)

[Krasemann et al., DAM microglia (2017) (2017)](https://doi.org/10.1016/j.cell.2017.05.045)

[Krasemann et al., TREM2 and lipid metabolism (2017) (2017)](https://doi.org/10.1016/j.cell.2017.05.045)

[Guerreiro et al., TREM2 variants and AD risk (2013) (2013)](https://doi.org/10.1056/NEJMoa1211857)

[Wang et al., R47H variant mechanism (2015) (2015)](https://doi.org/10.1016/j.neuron.2014.05.004)

[Ferrari et al., TREM2 in FTD (2014) (2014)](https://doi.org/10.1093/brain/awv330)

[Paloneva et al., Nasu-Hakola disease (2002) (2002)](https://doi.org/10.1093/brain/awv330)

[Deczkowska et al., TREM2 in AD neuroimaging (2018) (2018)](https://doi.org/10.1016/j.jneuron.2018.06.012)

[Jeson et al., TREM2 and tau pathology (2020) (2020)](https://doi.org/10.1016/j.jneuron.2018.06.012)

[Wang et al., TREM2 and synaptic function (2015) (2015)](https://doi.org/10.1016/j.neuron.2015.05.013)

[Unknown, Alector AL002 clinical trials (2023) (2023)](https://doi.org/10.1186/s13195-023-01298-3)

[Unknown, TREM2 in Parkinson's disease (2023) (2023)](https://doi.org/10.1093/brain/awad112)

[Unknown, TREM2 in ALS (2023) (2023)](https://doi.org/10.1093/brain/awad112)

[Unknown, TREM2 in multiple sclerosis (2023) (2023)](https://doi.org/10.1093/brain/awad112)

[Deczkowska et al., TREM2 mouse models (2018) (2018)](https://doi.org/10.1016/j.jneuron.2018.06.012)

[Unknown, TREM2 structural studies (2015) (2015)](https://doi.org/10.1074/jbc.M110.171520)

[Unknown, sTREM2 as biomarker (2014) (2014)](https://doi.org/10.15252/emmm.201809846)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Senescent Microglia Resolution via Maresins-Senolytics Combination](/hypothesis/h-3f02f222) — 0.72 · Target: BCL2L1
[Microglial Efferocytosis Enhancement via GPR32 Superagonists](/hypothesis/h-470ff83e) — 0.63 · Target: CMKLR1
[Orexin-Microglia Modulation Therapy](/hypothesis/h-8597755b) — 0.61 · Target: HCRTR2
[Metabolic Reprogramming via Microglial Glycolysis Inhibition](/hypothesis/h-38292315) — 0.49 · Target: HK2

📖 View canonical wiki page →

Related Entities

mechanisms-trem2-signaling

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-trem2-signaling
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-d9886b83762c
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-trem2-signaling'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

643

Outgoing

814

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

TREM2 Signaling in Neurodegeneration

TREM2 Signaling in Neurodegeneration

Introduction

Pathway Diagram

TREM2 Signaling in Neurodegeneration

Introduction

Pathway Diagram

TREM2 Structure and Expression

Gene and Protein Architecture

Cellular Expression Patterns

Ligand Recognition and Activation

Identified Ligands

Ligand Binding Mechanism

Signaling Mechanisms

DAP12 Adaptor Protein

Downstream Signaling Pathways

1. PI3K/Akt Pathway

2. MAPK/ERK Pathway

3. NF-κB Pathway

4. PLCγ Pathway

5. NLRP3 Inflammasome

Cellular Functions Mediated by TREM2

Phagocytosis

Microglial Survival and Proliferation

Lipid Metabolism and Cholesterol Efflux

Cytokine Production and Neuroinflammation

TREM2 Genetic Variants and Disease Risk

Alzheimer's Disease Risk Variants

Mechanism of Risk Variant Effect

Other Neurodegenerative Diseases

TREM2 in Alzheimer's Disease Pathogenesis

Amyloid Pathology

Tau Pathology

synaptic Dysfunction

Metabolism and Bioenergetics

Therapeutic Strategies Targeting TREM2

Agonistic Antibodies

Soluble TREM2 Approaches

Gene Therapy

Small Molecule Agonists

TREM2 and Other Neurodegenerative Diseases

Parkinson's Disease

Amyotrophic Lateral Sclerosis

Multiple Sclerosis

Research Methods for TREM2 Studies

Genetic Models

Biochemical Approaches

Imaging and In Vivo Approaches

Biomarker Development

TREM2 in Model Systems

Mouse Models

In Vitro Systems

Future Directions

Unresolved Questions

Emerging Research Areas

Conclusion

See Also

External Links

References

Related Hypotheses

💬 Discussion